Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 73.7%

Neg 0% Neu 0% Pos 73.7%

Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.